EMS

Executive Summary

EMS is Brazil’s preeminent pharmaceutical company, commanding a leading position in the domestic generic, OTC, and specialty medicine markets. With a strong focus on advanced formulation and biosimilar development, the company leverages its deep regulatory expertise and extensive distribution network to capture market share across Latin America. Its therapeutic portfolio spans oncology, immunology, cardiology, and CNS, among others, supported by a robust manufacturing ecosystem. Having raised $500M and operating at a commercial stage, EMS is well-capitalized to pursue growth through product line extensions, biosimilar launches, and geographic expansion. Looking ahead, EMS is expected to benefit from the growing demand for affordable biologics and complex generics in emerging markets. The company’s pipeline includes several high-value biosimilar candidates targeting oncology and autoimmune diseases, with potential regulatory filings in 2026. Additionally, strategic partnerships with global innovators and investments in R&D for novel drug delivery systems could unlock new revenue streams. With its entrenched market position and scalable platform, EMS is poised to sustain double-digit growth as it capitalizes on the favorable regulatory tailwinds and increasing healthcare access in Latin America.

Upcoming Catalysts (preview)

• Q3 2026ANVISA approval of oncology biosimilar (bevacizumab or trastuzumab)65% success
• Q4 2026Launch of first-in-class CNS generic in Brazil after patent expiry70% success
• Q2 2026Strategic partnership or licensing deal for immunology pipeline in Latin America60% success